Evidence map›Paper›PMID 29793439›Full record

ArticleBMC cancer2018

KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.

Lakmini Mudduwa, Harshini Peiris, Shania Gunasekara, Deepthika Abeysiriwardhana, Nimsha Liyanage, Suresh K Rayala, Thusharie Liyanage

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Lack of WWC2 Protein Leads to Aberrant Angiogenesis in Postnatal Mice.International journal of molecular sciences · 2021
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lakmini MudduwaDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, 80000, Sri Lanka. lakminimudduwa@yahoo.com.
Harshini PeirisMedical Laboratory Science Degree Programme, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
Shania GunasekaraDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, 80000, Sri Lanka.
Deepthika AbeysiriwardhanaDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, 80000, Sri Lanka.
Nimsha LiyanageDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, 80000, Sri Lanka.
Suresh K RayalaDepartment of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, 600 036, India.
Thusharie LiyanageDepartment of Pathology, Faculty of Medicine, University of Ruhuna, Galle, 80000, Sri Lanka.
University of Ruhuna · LKIndian Institute of Technology Madras · IN

Funding

Ministry of Science, Technology and Research, Sri Lanka grant MTR/TRD/AGR/3/1/9
6 · The paper itself

Abstract

backgroundThis study was carried out to evaluate the prognostic value of KIBRA in breast cancer.

methodsThis retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features.

resultsA total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA-low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model.

conclusionOverall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy.

Indexed as

AdultBiomarkers, TumorBreastBreast NeoplasmsCell NucleusChemotherapy, AdjuvantCross-Sectional StudiesCytoplasmDisease-Free SurvivalFemaleHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsKaplan-Meier EstimateMiddle AgedNeoplasm Recurrence, LocalBiomarkers, TumorIntracellular Signaling Peptides and ProteinsPhosphoproteinsReceptors, EstrogenReceptors, ProgesteroneWWC1 protein, humanBreast cancerEndocrine therapyERKIBRARecurrence free survival

Identifiers

PMID29793439
PMCPMC5968668
OpenAlexW2805920458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.